1 day ago · INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance. "2024 was a highly successful year for Lilly," said David A. Ricks, Lilly's chair and CEO."We had major data readouts for tirzepatide in treating chronic disease associated with obesity, invested billions more in ...

1 day ago · INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance. "2024 was a ...

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

1 day ago · INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance. "2024 was a highly successful year for Lilly," said David A. Ricks , …

17 hours ago · Eli Lilly and Co reported a 32% increase in full-year revenue for 2024, exceeding guidance by $4 billion. The company achieved a 45% revenue growth in Q4 2024, driven by strong performance of new ...

1 day ago · Eli Lilly (NYSE: LLY) Q4 2024 Earnings Call Feb 06, 2025, 10:00 a.m. ET. Contents: ... Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

1 day ago · Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in …

1 day ago · Eli Lilly (LLY) reported strong Q4 2024 financial results with revenue increasing 45% to $13.53 billion, primarily driven by Mounjaro and Zepbound sales.Q4 EPS grew 102% to $4.88 on a reported basis and 114% to $5.32 on a non-GAAP basis. The company received FDA approval for Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity and Omvoh for Crohn's disease.

Jan 14, 2025 · For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro ® and $1.9 billion for Zepbound ®. In addition to the uptake of Mounjaro and Zepbound, Lilly saw strong performance from its oncology, immunology and ...

1 day ago · INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance. "2024 was a ...